Annals of neurology
-
Annals of neurology · Jul 2012
Randomized Controlled Trial Multicenter StudyDonepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.
Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled exploratory phase 2 trial. ⋯ Donepezil at 5 and 10mg/day produces significant cognitive, behavioral, and global improvements that last at least 12 weeks in DLB patients, reducing caregiver burden at the highest dose. Donepezil is safe and well tolerated.